Age-related muscle dysfunction and sarcopenia are the main causes of physical disability in the elderly, and currently there is a lack of feasible treatment strategies. Recently, researchers have discovered that sphingolipids (ceramides) accumulate in the skeletal muscle of mice

Age-related muscle dysfunction and sarcopenia are the main causes of physical disability in the elderly, and currently there is a lack of feasible treatment strategies.

Recently, researchers have discovered that sphingolipids (ceramides) accumulate in mouse skeletal muscle with aging. Genetic and drug inhibition of sphingolipid synthesis can prevent age-related decline in muscle mass while enhancing strength and athletic ability.

Related research was published in "Nature Aging", the article is titled: "Sphingolipids accumulate in aged muscle, and their reduction counteracts sarcopenia".

Sphingolipid (ceramide) is familiar to everyone as a repair ingredient widely added to skin care products. It is a relatively special lipid . Researchers observed that the skeletal muscles of mice accumulate a type of substance called ceramide during the aging process. The accumulation of ceramide in skeletal muscle is closely related to the decline of muscle mass with aging. Inhibition of sphingolipid synthesis by

increases myogenic potential and promotes protein synthesis . In the sphingolipid pathway, the researchers found that accumulation of dihydroceramide is the culprit that interferes with homeostasis in myofibrils.

The relevance of the sphingolipid pathway in human aging has been demonstrated in two cohorts, using data from two cohorts, the British Biobank and the Helsinki birth cohort. Researchers examined thousands of people in their 70s and 80s and found that about 25% of them carried a special form of a gene that led to fewer products in the ceramide synthesis pathway in muscles. These older people were also generally stronger and could walk longer distances. Reduced gene expression variants of SPTLC1 and DEGS1 are associated with improved and reduced health, respectively, in older adults. These findings identify sphingolipid synthesis inhibition as an attractive therapeutic strategy for age-related sarcopenia and co-occurring pathologies.

related personnel are also working on the development of , an inhibitor of the ceramide synthesis pathway, and testing it in humans.

cell related clinical drugs development, mycoplasma detection is essential. MB qPCR mycoplasma detection kit has high sensitivity and has been verified by the European Pharmacopoeia method. It is convenient, fast and highly reliable.